Compositions of CpG and saponin adjuvants and uses thereof

Details Compositions of CpG and saponin adjuvants and uses thereof Compositions of CpG and saponin adjuvants and uses thereof

2006-03-10

2010-12-28

Minnifield, N. M (Department: 1645)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S184100, C424S278100

Reexamination Certificate

active

07858589

ABSTRACT:
Vaccine compositions of immunostimulatory oligonucleotides and saponin adjuvants and antigens and the use thereof for stimulating immunity, enhancing cell-mediated immunity, and enhancing antibody production are disclosed. Also described are immune adjuvant compositions comprising immunostimulatory oligonucleotides and saponin adjuvants, as well as methods for increasing an immune response using the same.

REFERENCES:
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 5023243 (1991-06-01), Tullis
patent: 5057540 (1991-10-01), Kensil et al.
patent: 5273965 (1993-12-01), Kensil et al.
patent: 5352449 (1994-10-01), Beltz et al.
patent: 5443829 (1995-08-01), Kensil et al.
patent: 5583112 (1996-12-01), Kensil et al.
patent: 5650398 (1997-07-01), Kensil et al.
patent: 5808024 (1998-09-01), Sasaki et al.
patent: 5968909 (1999-10-01), Agrawal et al.
patent: 5977081 (1999-11-01), Marcianai
patent: 6013258 (2000-01-01), Urban et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: 6214806 (2001-04-01), Krieg et al.
patent: 6218371 (2001-04-01), Krieg et al.
patent: 6231859 (2001-05-01), Kensil
patent: 6239116 (2001-05-01), Krieg et al.
patent: 6406705 (2002-06-01), Davis et al.
patent: 6429199 (2002-08-01), Krieg et al.
patent: 6524584 (2003-02-01), Kensil
patent: 6544518 (2003-04-01), Friede et al.
patent: 6558670 (2003-05-01), Friede et al.
patent: 6645495 (2003-11-01), Kensil et al.
patent: 7049302 (2006-05-01), Kensil
patent: 7399472 (2008-07-01), Friede et al.
patent: 7488490 (2009-02-01), Davis et al.
patent: 7550145 (2009-06-01), O'Hagan et al.
patent: 2001/0034330 (2001-10-01), Kensil et al.
patent: 2002/0164341 (2002-11-01), Davis et al.
patent: 2003/0091599 (2003-05-01), Davis et al.
patent: 2003/0161834 (2003-08-01), Friede et al.
patent: 2003/0224010 (2003-12-01), Davis et al.
patent: 2006/0177458 (2006-08-01), Kensil
patent: 2006/0239963 (2006-10-01), Morein et al.
patent: 2008/0311156 (2008-12-01), Friede et al.
patent: 2009/0047306 (2009-02-01), Nash et al.
patent: 9908885 (1999-04-01), None
patent: 1005368 (2000-06-01), None
patent: 2001503267 (2001-03-01), None
patent: 2001513776 (2001-09-01), None
patent: WO 95/08350 (1995-03-01), None
patent: WO 95/26204 (1995-10-01), None
patent: WO 96/11711 (1996-04-01), None
patent: WO 96/38161 (1996-12-01), None
patent: WO 98/18810 (1998-05-01), None
patent: WO 98/37919 (1998-09-01), None
patent: WO 98/40100 (1998-09-01), None
patent: WO 98/52581 (1998-11-01), None
patent: WO 98/55495 (1998-12-01), None
patent: WO 99/58118 (1999-11-01), None
patent: WO 99/61056 (1999-12-01), None
patent: WO 99/62923 (1999-12-01), None
patent: WO 00/21556 (2000-04-01), None
patent: WO 00/62800 (2000-10-01), None
patent: WO 02/32450 (2002-04-01), None
patent: WO 03/026688 (2003-04-01), None
patent: WO 03/030934 (2003-04-01), None
patent: WO 03/039595 (2003-05-01), None
patent: WO 03/094963 (2003-11-01), None
Rafi-Janajreh et al, Experimental Parasitology, 2002, 101:3-12.
Singh et al, Nature Biotechnology, Nov. 1999, 17:1075-1081.
Qiao et al, Hepatology, 2003, 37:52-59.
Kensil, In: Immunopotentiators in Modern Vaccines, ed. Virgil et al, 2006, pp. 109-122.
McCluskie et al, Current Drug Targets—Infectious Disorders, 2001, 1:263-271.
Pichichero, Human Vaccines, Jul./Aug. 2008, 4/4:262-270.
Fraser et al, Expert Rev. Vaccines, 2007, 6/4:559-578.
Kensil et al, Frontiers in Bioscience, Sep. 1, 2004, 9:2972-2988.
Krieg et al, Trends in Microbiology, Jun. 2001, 9/8:249-252.
Verthelyi et al, Clinical Immunology, 2003, 109:64-71.
Lin et al, J. Invest. Medicine, Sep. 1997, 45/7:333A (abstract only).
Yamamoto et al, Antisense Research and Development, 1994, 4:119-122.
Krieg et al, Immunology Today, 2000, 21/10:521-526.
McCluskie et al, Mol. Med., 1999, 5/5:287-300.
Ballas et al., 1996, “Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA,” J. Immunol. 157:1840-1845.
Cowdery et al., 1996, “Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides,” J. Immunol. 156:4570-1475.
Krieg et al., 1996, “CpG motifs in bacterial DNA trigger direct B-cell activation,” Nature 374:546-549.
Declaration of Charlotte Kensil under 37 CFR § 1.132, dated Apr. 23, 2004, of U.S. Appl. No. 09/369,941.
Office Action, dated Jan. 18, 2001, of U.S. Appl. No. 09/369,941.
Office Action, dated Mar. 14, 2002, of U.S. Appl. No. 09/369,941.
Advisory Action, dated Sep. 26, 2002, of U.S. Application No. 09/369,941.
Office Action, dated Jan. 31, 2003, of U.S. Application No. 09/369,941.
Office Action, dated Oct. 27, 2003, of U.S. Application No. 09/369,941.
Advisory Action and Examiner Interview Summary Record, dated Apr. 28, 2004, of U.S. Appl. No. 09/369,941.
Office Action, dated Mar. 2, 2005, of U.S. Appl. No. 09/369,941.
Examiner Interview Summary Record, dated Jul. 6, 2005, of U.S. Appl. No. 09/369,941.
Examiner Interview Summary Record, dated Nov. 17, 2005, of U.S. Appl. No. 09/369,941.
Agrawal et al., Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Natl Acad Sci USA. 1988, 85(19):7079-7083.
Agrawal S., Antisense oligonucleotides as antiviral agents. Trends Biotechnol. 1992, 10(5):152-158.
Beaucage et al., Deoxynucleotide phosphoramidites—A new class of key intermediates for deoxypolynucleotide synthesis. Tet. Let. 1981, 22:1859-1862.
Boggs et al., Characterization and modulation of immune stimulation by modified oligonucleotides. Antisense Nucleic Acid Drug Dev. 1997, 7(5):461-471.
Campbell & Peerbaye, Saponin.Res. Immuno. 1992, 143:526-530.
Carson et al., Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J. Exp. Med. 1997, 186(10):1621-1622.
Chavali & Campbell, Immunomodulatory Effects of Orally-Administered Saponins and Nonspecific Resistance Against Rabies Infection.Int. Archs. Allergy Appl. Immun. 1987, 84:129-134.
Chavali et al., Immunopotentiation by Orally-AdministeredQuillajaSaponins: Effects in Mice Vaccinated Intraperitoneally Against Rabies,Clin Exp. Immunol. 1988, 74:339-343.
Chavali et al., An In Vitro Study of Immunomodulatory Effects of Some Saponins.Int. J. Immunopharmac. 1987, 9(6):675-683.
Dalsgaard, K. A study of the isolation and characterization of the saponinquil a. Acta Veterinia Scandinavica1978, 69:1-40.
Elkins et al., Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol. 1999, 162(4):2291-2298.
Froehler B, Deoxynucleoside H-Phosphate diester intermediates in the synthesis of internucleotide phosphate analogues. Tet. Let. 1986, 27:5575.
Froehler et al., Synthesis of DNA via deoxynucleoside H-phosphonate intermediates. Nucleic Acids Res. 1986, 14(13):5399-5407.
Gaffney et al., Large-scale oligonucleotide synthesis by the H-Phosphonate method. Tet. Let. 1988, 29:2619-2622.
Garegg et al., Nucleoside H-phosphonates III. Chemical synthesis of oligodeoxyribonucleotides by the hydrogenphosphonate approach. Tet. Let. 1986, 27:4051-4054.
Garegg et al., Nucleoside H-phosphonates IV. Automated solid phase synthesis of oligoribonucleotides by the hydrogenphosphonate approach. Tet. Let. 1986, 27:4055-4058.
Goodchild J. Conjugates of oligonucleotides and modified oligonucleotides: a review of their synthesis and properties. Bioconjugate Chem. 1990, 1:165.
Higuchi et al., Structure of desacylsaponins obtained from the bark ofQuillaja saponaria. Phytochemistery 26:229-235, 1987.
Kensil et al., Structure/Function relationship in adjuvants fromQuillaja saponaria Molina. Vaccine 92 (Cold Spring Harbor Laboratory Press) 1992,pp. 35-40.
Kim et al., Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUCI-KLH and GD3-KLH conjugates. Vaccine. 2001, 19(4-5):530-537.
Kirby et al., Effects of anticholinesterase drugs tacrine and E2020, the 5-HT3 antagonist ondansetron, and the H3 antagonist thioperamide, in models of cognition and cholinergic

Affiliated with

Also associated with

Rating

Compositions of CpG and saponin adjuvants and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions of CpG and saponin adjuvants and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions of CpG and saponin adjuvants and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4160140